GARDNER, Mass., March 20, 2025 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ"...
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
Conference call will be held today, Thursday, March 20 at 9:00 am ETCARMEL, Ind., March 20, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating...
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
GAITHERSBURG, Md., March 13, 2025 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT),...
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
GAITHERSBURG, Md., March 12, 2025 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT),...
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
CARMEL, Ind., March 12, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized...
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activitiesGAITHERSBURG, Md., March 12, 2025 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and...
IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference
WINTER SPRINGS, Fla., March 10, 2025 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) today announced that it will participate in the 37th Annual Roth Conference. Iradimed's CFO, Jack Glenn, and CCO, Jeff Chiprin, will host one-on-one meetings between company...
Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board
GARDNER, Mass., March 04, 2025 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its...
InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024
Full Year 2024 vs. Full Year 2023: Record Net Revenues: $134.9 million, a 7% increase Patient Services Revenue: $80.4 million - Device Solutions Revenue: $54.5 million, increases of 5% and 11% Adjusted EBITDA (non-GAAP): $25.3 million, a 13% increase Record Operating...
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
GAITHERSBURG, Md., Feb. 26, 2025 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...